CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or <i>TP53</i> Mutations
Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Franck Morschhauser(Hôpital Claude Huriez), Rosemary Harrup(University of Tasmania), Yanwen Jiang, Oscar Cazares, Luca Laurenti(Sapienza University of Rome), Simona Barlera, Michelle Boyer(Amgen (United States)), Roberto Marasca(University of Modena and Reggio Emilia), Marcus Lefebure(Peter MacCallum Cancer Centre), Paolo Sportoletti(University of Perugia), Stephen P. Mulligan(Royal North Shore Hospital), Emmanuelle Ferrant(Hôpital Lyon Sud), Stephen Opat(Monash Health), Adalberto Ibatici(Ospedale Policlinico San Martino), Luis Felipe Casado Montero(Complejo Hospitalario Universitario de Toledo)
Cited by 3
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907